IOVacc is a biotechnology company developing new drugs in clinical stages. We develop breakthrough genetic and immunotherapies in the field of metabolic diseases and immuno-oncology. The purpose of our drugs is to treat rare and complex diseases using the immune system and the transciptome.
IOVacc is born after the identification of a need for new and innovative programs in the field of transciptome discoveries. With this in mind, the team got down to work “scouting” intense for several months, peering closely dozens of programs (patents) carried by academic organizations in Europe and North America. The choice of the founders fell on proteins and miRNA involved in the new cell signaling pathways.
Our science is on 2 fields: our expertise in miRNA for metabolic diseases and immuno-oncology, by the way of our new platform of miRNA discovery.
IOVacc’s pipeline consists of miRNA delivered by new vectors such as LNP (Lipid Nano-Particules).
The IOVacc technological approach is unique and offers efficiency and breakthrough results.